<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 60-year-old Japanese man with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and effort <z:mp ids='MP_0006112'>angina</z:mp> was referred to our clinic for treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The patient was transfusion-dependent and displayed <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (CAD) with 99% obstruction of the left anterior descending coronary artery </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment comprised reduced-intensity hematopoietic stem cell transplantation with administration of fludarabine phosphate (180 mg/m(2)) and <z:chebi fb="0" ids="28901">busulfan</z:chebi> (8 mg/kg), followed by allogeneic peripheral blood stem cell transplantation from an HLA-matched sister </plain></SENT>
<SENT sid="3" pm="."><plain>The regimen was well tolerated, and engraftment occurred rapidly without any therapy-related complications, including cardiovascular attack </plain></SENT>
<SENT sid="4" pm="."><plain>Sex chromosome analysis by fluorescence in situ hybridization revealed complete donor chimerism on day 29 for bone marrow cells and on day 59 for peripheral blood leukocytes </plain></SENT>
<SENT sid="5" pm="."><plain>The patient became transfusion-independent on posttransplantation day 8 </plain></SENT>
<SENT sid="6" pm="."><plain>As of 22 months postoperatively, he remains well, with 100% Karnofsky performance status, a limited type of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e>, and no recurrence of disease </plain></SENT>
<SENT sid="7" pm="."><plain>The clinical course of the patient suggests that this preparative regimen allows safe allogeneic stem cell transplantation for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with severe CAD </plain></SENT>
</text></document>